PureTech Health Dirección

Dirección controles de criterios 1/4

El CEO de PureTech Health es Bharatt Chowrira , nombrado en Apr 2024, tiene una permanencia de menos de un año. compensación anual total es $2.49M, compuesta por 23.1% salario y 76.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.42% de las acciones de la empresa, por valor de €2.08M. La antigüedad media del equipo directivo y de la junta directiva es de 0.7 años y 8.1 años, respectivamente.

Información clave

Bharatt Chowrira

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO	23.1%
Permanencia del CEO	less than a year
Participación del CEO	0.4%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bharatt Chowrira en comparación con los beneficios de PureTech Health?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$82m
Mar 31 2024	n/a	n/a	-US$74m
Dec 31 2023	US$2m	US$575k	-US$66m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$49m
Dec 31 2022	US$988k	US$530k	-US$50m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$1m	US$500k	-US$61m

Compensación vs. Mercado: La compensación total de Bharatt($USD2.49M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.03M).

Compensación vs. Ingresos: La compensación de Bharatt ha aumentado mientras la empresa no es rentable.

CEO

Bharatt Chowrira (59 yo)

less than a year

Permanencia

US$2,490,425

Compensación

Dr. Bharatt M. Chowrira, J. D. Ph. D. served as Chief Business and Operating Officer at PureTech Health plc. since January 2022 until 2024 and serves as its Chief Executive Officer from April 09, 2024 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bharatt Chowrira	CEO & Executive Director	less than a year	US$2.49m	0.42% € 2.1m
Daphne Zohar	Founder	no data	US$4.74m	3.35% € 16.5m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.15% € 5.7m
Eric Elenko	Co-Founder & President	less than a year	sin datos	sin datos
David Elmaleh	Co-Founder & Senior Advisor	no data	sin datos	sin datos
Lauren White	Chief Financial Officer	no data	sin datos	sin datos
Eric Green	Chief Operating Officer	less than a year	sin datos	sin datos
Allison Talbot	Head of Communications & Investor Relations	no data	sin datos	sin datos
Charles Sherwood	General Counsel & Company Secretary	less than a year	sin datos	sin datos
Spencer Ball	Senior Vice President of Human Resources	4.3yrs	sin datos	sin datos
Aleksandra Filipovic	Head of Oncology	4.3yrs	sin datos	sin datos
Cheryl Murphy	Head of Grants Management & Strategy	4.3yrs	sin datos	sin datos

0.7yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0VQ no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bharatt Chowrira	CEO & Executive Director	3.8yrs	US$2.49m	0.42% € 2.1m
Daphne Zohar	Founder	less than a year	US$4.74m	3.35% € 16.5m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.15% € 5.7m
David Elmaleh	Co-Founder & Senior Advisor	no data	sin datos	sin datos
Raju Kucherlapati	Chair & Senior Independent Director	10.8yrs	US$172.50k	1.05% € 5.2m
John LaMattina	Independent Non-Executive Director	15.8yrs	US$137.75k	0.61% € 3.0m
Bennett Shapiro	Board Advisor	4.4yrs	US$68.94k	sin datos
R. Anderson	Advisor	8.1yrs	sin datos	sin datos
James Collins	Advisor	9yrs	sin datos	sin datos
Donald Ingber	Senior Advisor	8.8yrs	sin datos	sin datos
Frederick Frank	Senior Advisor	no data	sin datos	sin datos
Sharon Barber-Lui	Independent Non-Executive Director	2.7yrs	US$135.00k	0.016% € 79.6k

8.1yrs

Permanencia media

74yo

Promedio de edad

Junta con experiencia: La junta directiva de 0VQ se considera experimentada (8.1 años de antigüedad promedio).

PureTech Health Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

Recent updates

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

New major risk - Revenue and earnings growth

New minor risk - Share price stability

First half 2024 earnings released: US$0.15 loss per share (vs US$0.09 loss in 1H 2023)

New major risk - Revenue and earnings growth

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in FY 2022)

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

New minor risk - Share price stability

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

First half 2023 earnings released: US$0.09 loss per share (vs US$0.098 loss in 1H 2022)

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in FY 2021)

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

First half 2022 earnings released: US$0.098 loss per share (vs US$0.26 loss in 1H 2021)

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.021 profit in FY 2020)

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought €85k worth of stock

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS

First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020)

President recently bought €97k worth of stock

PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202

President recently bought €81k worth of stock

PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics.

Puretech’s Gelesis Presents Plenity Data at American Association of Clinical Endocrinology 2021

COO, Secretary & Executive Director has left the company